Abstract
To search for potential mechanism that might alter synaptic transmission following Aβ increase we have examined the presynaptic component of transmitter release. As parameters of synaptic transmission that might underlie presynaptic mechanisms, we have used paired-pulse facilitation (PPF), post-tetanic potentiation (PTP), and synaptic fatigue (SF) at the connection between the hippocampal Schaffer-collateral pathway and CA1 pyramidal neurons in ∼5 month old double transgenic mice overexpressing the mutated form of amyloid precursor protein (APPK670N, M671L) and presenilin 1 (PS1M146V). While the presynaptic mechanisms of PPF and PTP were not compromised in the APP / PS1 mice, SF was more pronounced in the double transgenic animals. The percentage of the 40th fEPSP slope over the first during the tetanus was 18 ± 3% in APP / PS1 vs. 26 ± 2% in WT. Thus, it is likely that presynaptic mechanisms underlying SF but not PPF and PTP, may account for synaptic dysfunction in APP / PS1 mice.
Keywords: synapse, amyloid, synaptic fatigue, post-tetanic potentiation, paired pulse facilitation, neurotransmitter release, alzheimers disease
Current Alzheimer Research
Title: Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Hong Zhang, Bing Gong, Shumin Liu, Mauro Fa, Ipe Ninan, Agnieszka Staniszewski and Ottavio Arancio
Affiliation:
Keywords: synapse, amyloid, synaptic fatigue, post-tetanic potentiation, paired pulse facilitation, neurotransmitter release, alzheimers disease
Abstract: To search for potential mechanism that might alter synaptic transmission following Aβ increase we have examined the presynaptic component of transmitter release. As parameters of synaptic transmission that might underlie presynaptic mechanisms, we have used paired-pulse facilitation (PPF), post-tetanic potentiation (PTP), and synaptic fatigue (SF) at the connection between the hippocampal Schaffer-collateral pathway and CA1 pyramidal neurons in ∼5 month old double transgenic mice overexpressing the mutated form of amyloid precursor protein (APPK670N, M671L) and presenilin 1 (PS1M146V). While the presynaptic mechanisms of PPF and PTP were not compromised in the APP / PS1 mice, SF was more pronounced in the double transgenic animals. The percentage of the 40th fEPSP slope over the first during the tetanus was 18 ± 3% in APP / PS1 vs. 26 ± 2% in WT. Thus, it is likely that presynaptic mechanisms underlying SF but not PPF and PTP, may account for synaptic dysfunction in APP / PS1 mice.
Export Options
About this article
Cite this article as:
Zhang Hong, Gong Bing, Liu Shumin, Fa Mauro, Ninan Ipe, Staniszewski Agnieszka and Arancio Ottavio, Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585936
DOI https://dx.doi.org/10.2174/1567205053585936 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Conference Report: The American Association for the Advancement of Science (AAAS), 180th Annual Meeting Chicago, IL, USA Feb 13-17, 2014 “Meeting Global Challenges: Discoveries & Innovation”
CNS & Neurological Disorders - Drug Targets Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Neuronal Death and Survival Under Oxidative Stress in Alzheimer and Parkinson Diseases
CNS & Neurological Disorders - Drug Targets Reserve Mechanisms in Neurodegenerative Diseases: From Bench to Bedside and Back Again
Current Medicinal Chemistry Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Clinically Relevant Pharmacokinetic Herb-drug Interactions in Antiretroviral Therapy
Current Drug Metabolism Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine The Mechanism of Memory Impairment Induced by Aβ Chronic Administration Involves Imbalance between Cytokines and Neurotrophins in the Rat Hippocampus
Current Alzheimer Research Impaired Quality Control of Mitochondria Underlying the Pathogenesis of Alzheimer's Disease
Current Drug Targets Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Properties of CA3 Dendritic Excrescences in Alzheimers Disease
Current Alzheimer Research Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Alzheimer's Disease-Like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates
Current Alzheimer Research Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
Current Neuropharmacology Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Mechanisms of Synaptic Homeostasis in Alzheimers Disease
Current Alzheimer Research